Metabolism of ticagrelor in patients with acute coronary syndromes. [PDF]
© The Author(s) 2018Ticagrelor is a state-of-the-art antiplatelet agent used for the treatment of patients with acute coronary syndromes (ACS). Unlike remaining oral P2Y12 receptor inhibitors ticagrelor does not require metabolic activation to exert its ...
B Ibanez +41 more
core +2 more sources
Rationale and design of "Can Very Low Dose Rivaroxaban (VLDR) in addition to dual antiplatelet therapy improve thrombotic status in acute coronary syndrome (VaLiDate-R)" study : A randomised trial modulating endogenous fibrinolysis in patients with acute coronary syndrome [PDF]
© The Author(s) 2019. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the ...
Gorog, Diana A +5 more
core +2 more sources
Antagonizing P2Y12 Receptor Inhibitors: Current and Future Options [PDF]
AbstractThere are clinical scenarios where the balance between the risk of ischemic and bleeding events leads to the clinical decision to reverse the antiplatelet effect of P2Y12 receptor inhibitors. These scenarios comprise emergency situations such as active severe bleeding, urgent procedures with presumed high bleeding risk, or major trauma with ...
Trenk, Dietmar +7 more
openaire +3 more sources
After spinal cord injury, adult microglia remain persistently activated with chronic PRMT6 (protein arginine methyltransferase 6) upregulation. Prmt6 deficiency or inhibition reestablishes microglial homeostasis and promotes a scar‐limited repairment, enhancing axonal regrowth.
Weilin Peng +9 more
wiley +1 more source
Genotype-Guided Use of P2Y12 Inhibitors: A Review of Current State of the Art
The pharmacodynamics of the purinergic receptor type Y, subtype 12 (P2Y12) inhibitors has evolved. Our understanding of the metabolism of P2Y12 inhibitors has revealed polymorphisms that impact drug metabolism and antiplatelet efficacy, leading to ...
Abdullah Al-abcha +6 more
doaj +1 more source
Assessing a 600-mg Loading Dose of Clopidogrel 24 Hours Prior to Pipeline Embolization Device Treatment [PDF]
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 days before pipeline aneurysm treatment. Our study assessed the safety and efficacy of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device ...
Atallah, MD, Elias +9 more
core +2 more sources
Cold Gas Plasma Induces Platelet Activation and Hemostasis in Native and Anticoagulated Human Blood
Cold physical gas plasma induces platelet activation and hemostatic responses in native and anticoagulated human blood. Treatment efficacy depends on plasma parameters, including gas composition, distance, and exposure mode, which govern reactive species delivery and energy transfer.
Sander Bekeschus +5 more
wiley +1 more source
P2 purinoceptors signaling in fibroblasts of rat subcutaneous tissue [PDF]
Mestrado em Biologia Molecular e CelularO tecido conjuntivo parece estar envolvido na génese de diversas condições patológicas. O aumento da rigidez do tecido conjuntivo, resultante da fibrose, pode constituir um factor importante no mecanismo patogénico
Reis, Carla Patrícia da Silva e Sousa
core +1 more source
Stabilizing role of platelet P2Y(12) receptors in shear-dependent thrombus formation on ruptured plaques [PDF]
Background: In most models of experimental thrombosis, healthy blood vessels are damaged. This results in the formation of a platelet thrombus that is stabilized by ADP signaling via P2Y(12) receptors.
J. J. J. van Giezen +9 more
core +3 more sources
ABSTRACT Background The residual Gensini score (rGS) was developed to quantify the severity of coronary atheroma burden after coronary revascularisation. The predictive value of the rGS for clinical outcomes in patients with ST‐segment elevation myocardial infarction (STEMI) remains unexplored.
Batric Popovic +8 more
wiley +1 more source

